A peptide fragment from collagen production correlates strongly with liver scarring severity, potentially offering a blood test alternative to liver biopsy.
r = 0.733Correlation between blood procollagen peptide levels and actual liver fibrosis area measured by biopsy
What the researchers found
Serum amino-terminal type III procollagen peptide levels showed a strong positive correlation with the degree of liver fibrosis (r = 0.733, p < 0.001) in patients with alcoholic liver disease. In contrast, serum proline levels and standard liver function tests failed to correlate significantly with the actual extent of fibrotic tissue measured by morphometric analysis of liver biopsies.
Why it matters
Detecting liver fibrosis early in alcoholic liver disease is critical for preventing progression to cirrhosis. Standard blood tests often miss fibrosis. This study identified a peptide biomarker — amino-terminal type III procollagen peptide — that tracks closely with the actual amount of scar tissue in the liver, offering a potential non-invasive way to monitor disease severity.
The numbers in context
r = 0.733, p < 0.001
How the study worked
Cross-sectional study comparing serum proline and amino-terminal type III procollagen peptide levels against liver biopsy morphometric analysis in 31 patients with alcoholic liver disease and 15 healthy controls.
Who was studied
31 adults with alcoholic liver disease (ranging from nonspecific changes to cirrhosis) and 15 healthy controls
What this study cannot tell us
Small sample size of 31 patients limits generalizability. The cross-sectional design cannot establish whether peptide levels change over time with disease progression. The study is from 1986 and newer fibrosis markers have since been developed.
How to read the evidence
This is a small cross-sectional study with 46 participants. The strong correlation is notable but the sample size is limited and the study design cannot prove causation.
When this study was published
Published in 1986, this is a foundational study in peptide-based fibrosis diagnostics. Its core concept has been validated and expanded by decades of subsequent research.
The bigger picture
This 1986 study was an early demonstration that peptide biomarkers could detect organ damage that standard tests miss. The concept of using collagen-derived peptide fragments as fibrosis markers has since expanded into a broader field of non-invasive fibrosis diagnostics, influencing the development of modern scoring systems like FibroTest and ELF panels.
Questions still open
- How does this peptide biomarker compare to modern non-invasive fibrosis scores developed since this study?
- Can serial measurements of procollagen peptide levels track fibrosis regression after alcohol cessation?
- Does this biomarker perform similarly in non-alcoholic liver fibrosis?
Common questions
What is amino-terminal type III procollagen peptide?
Can this blood test replace a liver biopsy?
Read the original research
Evaluation of hepatic fibrosis by serum proline and amino-terminal type III procollagen peptide levels in alcoholic patients.
Digestive diseases and sciences, 31(7), 712-7
Citation
Tanaka, Y; Minato, Y; Hasumura, Y; Takeuchi, J. (1986). Evaluation of hepatic fibrosis by serum proline and amino-terminal type III procollagen peptide levels in alcoholic patients.. Digestive diseases and sciences, 31(7), 712-7.